According to documents submitted to the SEC, biotechnology company Avai Bio Inc and Ainnova Tech have agreed, as of May 7, 2026, to jointly terminate their previously established joint venture and related licensing agreements.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Debt and inflation become the biggest constraints! Deutsche Bank warns: The global market "policy safety net" is failing and future volatility may intensify
Deutsche Bank Research stated in its latest report that the era of large-scale policy interventions used to cushion global economic shocks over the past decades is coming to an end. The continuous rise in sovereign debt, high interest rates, and persistent inflation are all weakening the traditional “safety net” relied upon by governments and central banks.
Bellock executive Lee Young Hoon lifts stake to 0.99% from 0.56%
BUZZ - Australia's Maas Group hits all-time high after Meta Firmus deal
Japan’s Katayama says undervalued Yen generally poses problems
Crypto prices
More
